Karl Nägler

Managing Partner, Sofinnova

Karl Naegler is a Partner in the Sofinnova Capital Strategy. He joined us in September 2024, bringing a strong track record of 20 years of investment experience.

Before joining Sofinnova, he was a Managing Partner at Wellington Partners Life Sciences and before that, a Partner at Gimv. In those roles, he was instrumental in the success of several high-profile startups, from company formation to exit. These include Seamless Therapeutics, launched with a top syndicate of investors; Breath Therapeutics, a co-investment with Sofinnova, acquired by Zambon; Covagen, acquired by Johnson & Johnson, and Prosonix, acquired by Circassia Pharmaceuticals.

His career also includes key roles at Ventech and Atlas Venture. Karl earned his PhD in Molecular Neurobiology from the Max-Delbrück-Center for Molecular Medicine in Berlin followed by a position as Scientific Fellow at CNRS for Neurochemistry in Strasbourg.